The Prognostic Value of FET PET at Radiotherapy Planning in Newly Diagnosed Glioblastoma

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2016 Aug 25

PMID 27554774

Citations 35

Authors

Sidsel Hojklint Poulsen

Thomas Urup

Kirsten Grunnet

Ib Jarle Christensen

Vibeke Andree Larsen

Michael Lundemann Jensen

Per Munck Af Rosenschold

Hans Skovgaard Poulsen

Ian Law

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-F-fluoroethyl)-L-tyrosine (FET) PET as an independent prognostic biomarker.

Methods: We retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients. All patients were treated with temozolomide and radiation therapy (RT). CT/MR and FET PET scans were obtained postoperatively for RT planning. We used Cox proportional hazards models with OS and PFS as endpoints, to test the prognostic value of FET PET biological tumor volume (BTV).

Results: Median follow-up time was 14 months, and median OS and PFS were 16.5 and 6.5 months, respectively. In the multivariate analysis, increasing BTV (HR = 1.17, P < 0.001), poor performance status (HR = 2.35, P < 0.001), O(6)-methylguanine-DNA methyltransferase protein status (HR = 1.61, P = 0.024) and higher age (HR = 1.32, P = 0.013) were independent prognostic factors of poor OS. For poor PFS, only increasing BTV (HR = 1.18; P = 0.002) was prognostic. A prognostic index for OS was created based on the identified prognostic factors.

Conclusion: Large BTV on FET PET is an independent prognostic factor of poor OS and PFS in glioblastoma patients. With the introduction of FET PET, we obtain a prognostic index that can help in glioblastoma treatment planning.

Citing Articles

Added prognostic value of DCE blood volume imaging in patients with suspected recurrent or residual glioblastoma-A hybrid [F]FET PET/MRI study.

Henriksen O, Muhic A, Lundemann M, Larsson H, Lindberg U, Andersen T Neurooncol Adv. 2024; 6(1):vdae196.

PMID: 39664680 PMC: 11632823. DOI: 10.1093/noajnl/vdae196.

Automatic detection and delineation of pediatric gliomas on combined [F]FET PET and MRI.

Ladefoged C, Henriksen O, Mathiasen R, Schmiegelow K, Andersen F, Hojgaard L Front Nucl Med. 2024; 2:960820.

PMID: 39354975 PMC: 11440972. DOI: 10.3389/fnume.2022.960820.

Deep Learning Segmentation of Infiltrative and Enhancing Cellular Tumor at Pre- and Posttreatment Multishell Diffusion MRI of Glioblastoma.

Gagnon L, Gupta D, Mastorakos G, White N, Goodwill V, McDonald C Radiol Artif Intell. 2024; 6(5):e230489.

PMID: 39166970 PMC: 11427928. DOI: 10.1148/ryai.230489.

A prospective clinical study of the influence of oral protein intake on [F]FET-PET uptake and test-retest repeatability in glioma.

Chehri S, Henriksen O, Marner L, Christensen M, Muhic A, Poulsen H EJNMMI Res. 2024; 14(1):58.

PMID: 38922458 PMC: 11208353. DOI: 10.1186/s13550-024-01119-0.

A PET probe targeting polyamine transport system for precise tumor diagnosis and therapy.

Zhou M, Yin X, Chen B, Hu S, Zhou W Asian J Pharm Sci. 2024; 19(3):100924.

PMID: 38903130 PMC: 11186966. DOI: 10.1016/j.ajps.2024.100924.

References

Suchorska B, Jansen N, Linn J, Kretzschmar H, Janssen H, Eigenbrod S . Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84(7):710-9. DOI: 10.1212/WNL.0000000000001262. View

Munck Af Rosenschold P, Engelholm S, Ohlhues L, Law I, Vogelius I, Engelholm S . Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking. Acta Oncol. 2011; 50(6):777-83. DOI: 10.3109/0284186X.2011.584555. View

Jansen N, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S . Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med. 2014; 56(1):9-15. DOI: 10.2967/jnumed.114.144675. View

Munck Af Rosenschold P, Costa J, Engelholm S, Lundemann M, Law I, Ohlhues L . Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro Oncol. 2014; 17(5):757-63. PMC: 4482858. DOI: 10.1093/neuonc/nou316. View

Malmstrom A, Gronberg B, Marosi C, Stupp R, Frappaz D, Schultz H . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13(9):916-26. DOI: 10.1016/S1470-2045(12)70265-6. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Kracht L, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21):7163-70. DOI: 10.1158/1078-0432.CCR-04-0262. View

Piroth M, Holy R, Pinkawa M, Stoffels G, Kaiser H, Galldiks N . Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol. 2011; 99(2):218-24. DOI: 10.1016/j.radonc.2011.03.006. View

Michaelsen S, Christensen I, Grunnet K, Stockhausen M, Broholm H, Kosteljanetz M . Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer. 2013; 13:402. PMC: 3766209. DOI: 10.1186/1471-2407-13-402. View

10.

Salber D, Stoffels G, Oros-Peusquens A, Shah N, Reifenberger G, Hamacher K . Comparison of O-(2-18F-fluoroethyl)-L-tyrosine and L-3H-methionine uptake in cerebral hematomas. J Nucl Med. 2010; 51(5):790-7. DOI: 10.2967/jnumed.109.071423. View

11.

Pirotte B, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O . Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009; 64(3):471-81. DOI: 10.1227/01.NEU.0000338949.94496.85. View

12.

Huang R, Rahman R, Ballman K, Felten S, Anderson S, Ellingson B . The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2015; 22(3):575-81. DOI: 10.1158/1078-0432.CCR-14-3040. View

13.

Wester H, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M . Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999; 40(1):205-12. View

14.

Roder C, Bisdas S, Ebner F, Honegger J, Naegele T, Ernemann U . Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol. 2014; 40(3):297-304. DOI: 10.1016/j.ejso.2013.11.022. View

15.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

16.

Rachinger W, Goetz C, Popperl G, Gildehaus F, Kreth F, Holtmannspotter M . Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005; 57(3):505-11. DOI: 10.1227/01.neu.0000171642.49553.b0. View

17.

Piroth M, Prasath J, Willuweit A, Stoffels G, Sellhaus B, van Osterhout A . Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. Nucl Med Biol. 2013; 40(6):795-800. DOI: 10.1016/j.nucmedbio.2013.05.001. View

18.

Galldiks N, Stoffels G, Ruge M, Rapp M, Sabel M, Reifenberger G . Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013; 54(12):2046-54. DOI: 10.2967/jnumed.113.123836. View

19.

Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M . Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2014; 42(5):685-95. DOI: 10.1007/s00259-014-2959-4. View

20.

Mehrkens J, Popperl G, Rachinger W, Herms J, Seelos K, Tatsch K . The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol. 2008; 88(1):27-35. DOI: 10.1007/s11060-008-9526-4. View